Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Seeks New Homes For Assets Orphaned By R&D Reorg

This article was originally published in The Pink Sheet Daily

Executive Summary

New head of out-licensing takes on prospects cast off in Pfizer’s recent exit from non-“high priority” therapeutic areas.
Advertisement

Related Content

Pfizer Prunes Its Pipeline And Creates A Stockpile Of Compounds For Deals
Pfizer Prunes Its Pipeline And Creates A Stockpile Of Compounds For Deals
Pfizer Prunes Its Pipeline And Creates A Stockpile Of Compounds For Deals
Pfizer Halts Phase III Study Of Sutent In Advanced Breast Cancer
Pfizer Halts Phase III Study Of Sutent In Advanced Breast Cancer
Pfizer Backs Out Of Cardiovascular R&D
Pfizer Backs Out Of Cardiovascular R&D
Pfizer Spins Off Esperion While Retaining Former Subsidiary’s Top Compounds
Can Out-Partnering Help Vault Pfizer Over the "Second Cliff"?
Roche Global Head Of Pharma Partnering Dan Zabrowski: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)

Topics

Advertisement
UsernamePublicRestriction

Register

PS066985

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel